442 related articles for article (PubMed ID: 25544378)
1. Modulating the serotonin system in the treatment of major depressive disorder.
Morrissette DA; Stahl SM
CNS Spectr; 2014 Dec; 19 Suppl 1():57-67; quiz 54-7, 68. PubMed ID: 25544378
[TBL] [Abstract][Full Text] [Related]
2. Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants.
Pehrson AL; Sanchez C
Drug Des Devel Ther; 2015; 9():603-24. PubMed ID: 25653499
[TBL] [Abstract][Full Text] [Related]
3. Effects of serotonin in the hippocampus: how SSRIs and multimodal antidepressants might regulate pyramidal cell function.
Dale E; Pehrson AL; Jeyarajah T; Li Y; Leiser SC; Smagin G; Olsen CK; Sanchez C
CNS Spectr; 2016 Apr; 21(2):143-61. PubMed ID: 26346726
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of atypical antipsychotics in depressive syndromes].
Quintin P; Thomas P
Encephale; 2004; 30(6):583-9. PubMed ID: 15738862
[TBL] [Abstract][Full Text] [Related]
5. The under-recognized role of dopamine in the treatment of major depressive disorder.
Montgomery SA
Int Clin Psychopharmacol; 2008 Mar; 23(2):63-9. PubMed ID: 18301120
[TBL] [Abstract][Full Text] [Related]
6. Other Antidepressants.
Schwasinger-Schmidt TE; Macaluso M
Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
[TBL] [Abstract][Full Text] [Related]
7. Vortioxetine: a New Treatment for Major Depressive Disorder.
Connolly KR; Thase ME
Expert Opin Pharmacother; 2016; 17(3):421-31. PubMed ID: 26679430
[TBL] [Abstract][Full Text] [Related]
8. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data.
Sanchez C; Asin KE; Artigas F
Pharmacol Ther; 2015 Jan; 145():43-57. PubMed ID: 25016186
[TBL] [Abstract][Full Text] [Related]
9. Serotonin-induced hyperactivity in SSRI-resistant major depressive disorder patient-derived neurons.
Vadodaria KC; Ji Y; Skime M; Paquola A; Nelson T; Hall-Flavin D; Fredlender C; Heard KJ; Deng Y; Le AT; Dave S; Fung L; Li X; Marchetto MC; Weinshilboum R; Gage FH
Mol Psychiatry; 2019 Jun; 24(6):795-807. PubMed ID: 30700803
[TBL] [Abstract][Full Text] [Related]
10. New approaches to developing antidepressants by enhancing monoaminergic neurotransmission.
Bymaster FP; McNamara RK; Tran PV
Expert Opin Investig Drugs; 2003 Apr; 12(4):531-43. PubMed ID: 12665410
[TBL] [Abstract][Full Text] [Related]
11. Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials.
Huang KL; Lu WC; Wang YY; Hu GC; Lu CH; Lee WY; Hsu CC
Aust N Z J Psychiatry; 2014 Jul; 48(7):663-71. PubMed ID: 24604920
[TBL] [Abstract][Full Text] [Related]
12. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents.
Papakostas GI; Thase ME; Fava M; Nelson JC; Shelton RC
Biol Psychiatry; 2007 Dec; 62(11):1217-27. PubMed ID: 17588546
[TBL] [Abstract][Full Text] [Related]
13. Astroglial Serotonin Receptors as the Central Target of Classic Antidepressants.
Verkhratsky A; Parpura V; Scuderi C; Li B
Adv Neurobiol; 2021; 26():317-347. PubMed ID: 34888840
[TBL] [Abstract][Full Text] [Related]
14. Current and Future Perspectives on the Major Depressive Disorder: Focus on the New Multimodal Antidepressant Vortioxetine.
Orsolini L; Tomasetti C; Valchera A; Iasevoli F; Buonaguro EF; Fornaro M; Fiengo ALC; Martinotti G; Vellante F; Matarazzo I; Vecchiotti R; Perna G; Di Nicola M; Carano A; Di Bartolomeis A; De Giannantonio M; De Berardis D
CNS Neurol Disord Drug Targets; 2017; 16(1):65-92. PubMed ID: 27781949
[TBL] [Abstract][Full Text] [Related]
15. A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder.
Papakostas GI; Fava M
Eur Neuropsychopharmacol; 2007 Jan; 17(1):32-6. PubMed ID: 16762534
[TBL] [Abstract][Full Text] [Related]
16. Major depressive disorder and diabetes: does serotonin bridge the gap?
De Long NE; Stepita RA; Taylor VH; Holloway AC
Curr Diabetes Rev; 2015; 11(2):71-8. PubMed ID: 25705990
[TBL] [Abstract][Full Text] [Related]
17. A prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment.
Sagud M; Nikolac Perkovic M; Vuksan-Cusa B; Maravic A; Svob Strac D; Mihaljevic Peles A; Zivkovic M; Kusevic Z; Pivac N
Psychopharmacology (Berl); 2016 Sep; 233(17):3259-67. PubMed ID: 27356518
[TBL] [Abstract][Full Text] [Related]
18. Drugs which influence serotonin transporter and serotonergic receptors: Pharmacological and clinical properties in the treatment of depression.
Taciak PP; Lysenko N; Mazurek AP
Pharmacol Rep; 2018 Feb; 70(1):37-46. PubMed ID: 29309998
[TBL] [Abstract][Full Text] [Related]
19. The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder.
Sahli ZT; Banerjee P; Tarazi FI
Expert Opin Drug Discov; 2016; 11(5):515-23. PubMed ID: 26971593
[TBL] [Abstract][Full Text] [Related]
20. Monoamine neurocircuitry in depression and strategies for new treatments.
Hamon M; Blier P
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():54-63. PubMed ID: 23602950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
